Lantern Pharma Inc.
LTRN Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$0.64
KIRA · Stoqly’s AI analyst, in plain words
- Lantern Pharma Inc. lost $17.1M in fiscal 2025.
- Free cash flow was −$15.7M in fiscal 2025, — of revenue.
Market cap
$7.9M
P/E
—
Revenue
—
Net income
−$17.1M
Free cash flow
−$15.7M
Operating margin
—
Lantern Pharma Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$17.1M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Lantern Pharma Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Legal name
- Lantern Pharma Inc.
- CIK
- 0001763950
Lantern Pharma Inc. · LTRN
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$12.4M | −$14.3M | −$16.0M | −$20.8M | −$17.1M |
| Diluted EPS | −$1.13 | −$1.31 | −$1.47 | −$1.93 | −$1.57 |
| Cash | |||||
| Cash from operations | −$10.6M | −$12.8M | −$14.3M | −$17.8M | −$15.7M |
| Capital expenditure | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$10.6M | −$12.8M | −$14.4M | −$17.8M | −$15.7M |
| Share buybacks | $0.9M | $2.5M | $0.5M | — | — |
| Share count change | 153.3% | −0.5% | −0.1% | −0.7% | 1.3% |
| Debt and strength | |||||
| Cash and short-term investments | $70.7M | $55.2M | $41.3M | $24.0M | $10.1M |
| Shareholders' equity | $71.6M | $56.0M | $40.9M | $21.2M | $6.5M |
| Current ratio | 31.3x | 21.0x | 16.2x | 5.8x | 2.4x |
| Returns and quality | |||||
| Return on equity | −27.1% | −22.3% | −32.9% | −66.9% | −123.5% |
| Return on tangible equity | −17.3% | −25.4% | −39.0% | −98.1% | −262.0% |
| Altman Z'' | 35.6 | 23.4 | 14.9 | −5.1 | −33.2 |
Insiders bought, 12 months
$0.2M
2 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Lantern Pharma Inc. · LTRN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.64 a share, the company is worth $7.9M.
Source: SEC EDGAR XBRL filings (CIK 0001763950). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.